p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin

Cancer Research

Volumn 61, Issue 4, 2001, Pages 1508-1516

  Lin, Xinjian ^a   Ramamurthi, Krishnan ^a   Mishima, Misako ^a   Kondo, Akira ^a   Christen, Randolph D ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PROTEIN P53; TIOGUANINE; TOPOTECAN;

ARTICLE; CANCER RESISTANCE; CELL CYCLE; CHEMOTHERAPY; COLON CANCER; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; MISMATCH REPAIR; MUTAGENICITY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE PAIR MISMATCH; CELL CYCLE; CISPLATIN; COLORECTAL NEOPLASMS; DNA ADDUCTS; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MUTAGENESIS; PLATINUM; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035866361     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Experimental therapeutics and kinetics: Selection and overgrowth of specifically and permanently drug-resistant tumor cells
2. Point mutations of the topoisomerase Ila gene in patients with small lung cancer treated with etoposide
3. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells
4. Altered cell cycie arrest and gene amplification potential accompany loss of wild-type p53
5. Mutator phenotypes in human colorectal carcinoma cell lines
6. +tumor cells
7. An atkylation-toleration, mutator human cell line is deficient in strand-specific mismatch repair
8. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
9. Mutation of a mutL homolog in hereditary colon cancer
10. Identification of mismatch repair genes and their role in the development of cancer
11. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: Implications for tolerance to DNA methylation damage
12. Mismatch repair mutator phenotype confers resistance to temozolomide in human colon cancer cell lines
13. The role of DNA mismatch repair in platinum drug resistance
14. p53, the cellular gatekeeper for growth and division
15. Stabilized p53 facilitates aneuploid clonal divergence in colorectal cancer
16. p53 mutations in human cancers
17. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs
18. Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis- diamminedichloroplatinum(II)
19. cis-Platinum (11) diamine dichloride causes mutation, transformation, and sister-chromatid exchanges itl ill cultured mammalian cells
20. In vivo mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltranslerase gene
21. Effect of loss of DNA mismatch repair on development of topotecan-gemcitabine, and paclitaxel-resistant variants after exposure to cisplatin
22. The role of DNA mismatch repair in cisplatin nrutagenicity
23. A Microsatellite instability, mismatch repair deficiency, and genetic detect in human cancer cell lines
24. Human chromosome corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-nitroguanidine tolerance in colon tumor cells with homozygous hMLH/ mutation
25. 2-M cell cycle checkpoint arrest following ionizing radiation
26. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
27. A novel plasmid shuttle vector for the detection and analysis of microsatellite instability in cell lines
28. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines
29. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
30. Apoptotie death of tumor cells correlates with chemosensitivity, independent of p53 or Bcl-2
31. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
32. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
33. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and resistant human ovarian cancer cells
34. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
35. p53 modulates the effects of loss of DNA mismatch repair on the cytotoxicity and mutagenicity of hydrogen peroxide
36. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT
37. The role of DNA mismatch repair in drug resistance
38. 2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and deficient cells exposed to cisplatin
39. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair
40. Modulation of cisplatinum cytotoxicity by p53: Effect of p53-mediated apoptosis and DNA repair
41. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline
42. Inactivation p53 of enhances sensitivity to multiple chemotherapeutic agents
43. Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage
44. Effect of p 53 status on sensitivity to platinum complexes in a human ovarian cancer cell line
45. p53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53. p21, and/or gadd45 genes
46. Cells lacking CIP/WAFI genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
47. Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis
48. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine
49. Resistance to I-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutation with the deoxycytidine kinase gene
50. Resistance mechanism in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol)
51. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p 53 mutations
52. The ability of a variety of polymcrases to synthesize past site-specific cis-syn, trans-syn-11, (6-4). and Dewar photoproducts of thymidylyl-(3'- > 5')-thymidine
53. DNA polymerase mutagenic bypass and proof-reading of endogenous DNA lesions
54. DNA repair, DNA replication, and UV mutagenesis
55. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: Correlation with replicative bypass of platinum-DNA adducts
56. p53 modulation of TFIIH-associated nucleotide excision repair activity
57. Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair
58. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
59. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines